001     274067
005     20250119000318.0
024 7 _ |a 10.1002/trc2.70028
|2 doi
024 7 _ |a pmid:39759949
|2 pmid
024 7 _ |a pmc:PMC11696024
|2 pmc
024 7 _ |a altmetric:172970902
|2 altmetric
037 _ _ |a DZNE-2025-00048
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Brettschneider, Christian
|0 0000-0002-5280-1075
|b 0
245 _ _ |a Cost-effectiveness of a multicomponent intervention against cognitive decline.
260 _ _ |a Hoboken, NJ
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1736940770_13620
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The societal costs of dementia and cognitive decline are substantial and likely to increase during the next decades due to the increasing number of people in older age groups. The aim of this multicenter cluster-randomized controlled trial was to assess the cost-effectiveness of a multi-domain intervention to prevent cognitive decline in older people who are at risk for dementia.We used data from a multi-centric, two-armed, cluster-randomized controlled trial (AgeWell.de trial, ID: DRKS00013555). Eligible participants with increased dementia risk at baseline (Cardiovascular Risk Factors, Aging, and Incidence of Dementia/CAIDE Dementia Risk Score ≥ 9), 60-77 years of age, were recruited by their general practitioners, and assigned randomly to a multi-domain lifestyle intervention or general health advice. We performed a cost-effectiveness analysis from the societal perspective. The time horizon was 2 years. Health care utilization was measured using the 'Questionnaire for Health-Related Resource Use in Older Populations.' As effect measure, we used quality-adjusted life-years (QALYs) based on the 5-level EQ-5D version (EQ-5D-5L). We calculated the incremental cost-effectiveness ratios (ICER) and cost-effectiveness acceptability curves (CEAC) using the net-benefit approach. Exploratory analyses considering women and the EQ visual analogue scale (EQ VAS) were conducted.Data were available for 819 participants (mean age 69.0 [standard deviation (SD)5-level EQ-5D version 4.9]); 378 were treated in the intervention group and 441 in the control group. The participants in the intervention group caused higher costs (+€445.88 [SD: €1,244.52]) and gained additional effects (+0.026 QALY [SD: 0.020]) compared to the participants in the control group (the difference was statistically significant). The ICER was €17,149.23/QALY. The CEAC showed that the probability of the intervention being cost-effective was moderate, reaching 59% at a willingness-to-pay (WTP) of €50,000/QALY. The exploratory analyses showed promising results, especially in the female subsample.Considering aspects like the WTP and the limited time horizon, the multi-domain intervention was cost-effective compared to general health advice.The first German randomized controlled trial (RCT) evaluating a multicomponent approach against cognitive decline.We found a favorable incremental cost-effectiveness ratio.The probability of cost-effectiveness reached 78.6%.Women could be an important target group.A longer time horizon is needed.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a RCT
|2 Other
650 _ 7 |a cognitive decline
|2 Other
650 _ 7 |a cost‐effectiveness analysis
|2 Other
650 _ 7 |a dementia
|2 Other
650 _ 7 |a multicomponent intervention
|2 Other
650 _ 7 |a older individuals
|2 Other
650 _ 7 |a risk factors
|2 Other
700 1 _ |a Buczak-Stec, Elżbieta
|b 1
700 1 _ |a Luppa, Melanie
|b 2
700 1 _ |a Zülke, Andrea
|b 3
700 1 _ |a Michalowsky, Bernhard
|0 P:(DE-2719)2810763
|b 4
|u dzne
700 1 _ |a Rädke, Anika
|0 P:(DE-2719)9001134
|b 5
|u dzne
700 1 _ |a Bauer, Alexander
|b 6
700 1 _ |a Brütting, Christine
|b 7
700 1 _ |a Kosilek, Robert P
|b 8
700 1 _ |a Zöllinger, Isabel
|b 9
700 1 _ |a Döhring, Juliane
|b 10
700 1 _ |a Williamson, Martin
|b 11
700 1 _ |a Wiese, Birgitt
|b 12
700 1 _ |a Hoffmann, Wolfgang
|0 P:(DE-2719)2000040
|b 13
|u dzne
700 1 _ |a Frese, Thomas
|b 14
700 1 _ |a Gensichen, Jochen
|b 15
700 1 _ |a Kaduszkiewicz, Hanna
|b 16
700 1 _ |a Thyrian, Jochen René
|0 P:(DE-2719)2290613
|b 17
|u dzne
700 1 _ |a Riedel-Heller, Steffi G
|b 18
700 1 _ |a König, Hans-Helmut
|b 19
700 1 _ |a DE study group, AGEWELL.
|b 20
|e Collaboration Author
773 _ _ |a 10.1002/trc2.70028
|g Vol. 11, no. 1, p. e70028
|0 PERI:(DE-600)2832891-7
|n 1
|p e70028
|t Alzheimer's & dementia / Translational research & clinical interventions
|v 11
|y 2025
|x 2352-8737
856 4 _ |u https://pub.dzne.de/record/274067/files/DZNE-2025-00048%20SUP.zip
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/274067/files/DZNE-2025-00048.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/274067/files/DZNE-2025-00048.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:274067
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2810763
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9001134
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2000040
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2290613
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-25
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2023-08-25
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZH DEMENT-TRCI : 2022
|d 2023-08-25
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-04-16T15:13:10Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-04-16T15:13:10Z
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-25
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-25
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2021-04-16T15:13:10Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-25
920 1 _ |0 I:(DE-2719)5000067
|k AG Michalowsky
|l Patient-Reported Outcomes and Health Economics Research
|x 0
920 1 _ |0 I:(DE-2719)1510600
|k AG Hoffmann
|l Translational Health Care Research
|x 1
920 1 _ |0 I:(DE-2719)1510800
|k AG Thyrian
|l Interventional Health Care Research (IHCR)
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000067
980 _ _ |a I:(DE-2719)1510600
980 _ _ |a I:(DE-2719)1510800
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21